Prelude PRLD 深 滬
等待開盤 12-25 09:30:00 美东时间
2.23
+0.040
+1.83%
華盛通- 最 高2.33
- 今 開2.20
- 成交量 10.79万股
- 最 低 2.20
- 昨 收 2.19
- 總市值 1.26亿
- 52周最高 4.22
- 市盈率 靜 --
- 換手率 0.19%
- 52周最低 0.6101
- 委 比 -97.11%
- 總股本 5660.03万
- 歷史最高 95.375
- 量 比 0.21
- 振 幅 5.94%
- 歷史最低 0.6101
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Prelude Therapeutics在第67届美国血液学会年会上展示了其针对骨髓增殖性肿瘤（MPN）的两项重要研究进展。首先，其JAK2V617F选择性JH2抑制剂PRT12396在临床前研究中表现出显著的疾病修饰潜力，可选择性抑制突变JAK2活性而不影响正常JAK2功能。PRT12396已完成GLP毒理学研究，计划于2026年第一季度提交IND申请。其次，其靶向突变钙网蛋白（mCALR）的降解剂抗体偶联物（DAC）与CDK9降解剂负载结合，在临床前研究中显示了对恶性细胞的深度选择性杀伤，同时保留健康造血细胞，具有潜在的疾病修饰作用。两项研究均旨在为MPN患者提供创新的疾病修饰疗法。
12-06 16:00
Fed's Bowman says banking system remains 'sound and resilient'
Federal Reserve Vice Chair for Supervision Michelle Bowman said Tuesday the U.S. banking system is still "sound and resilient," as lenders continued to post robust capital ratios and large liquidity b...
12-02 23:44
Q3 earnings show firm revenue gains alongside softer low-income demand
S&P 500 companies continued to show robust revenue growth in Q3, according to Goldman Sachs, with real revenues excluding energy rising 4.1% year-over-year, outpacing the firm’s estimate of 2.2% real ...
12-02 22:39
Prelude Therapeutics Q3 EPS $(0.26) Beats $(0.36) Estimate, Sales $6.500M Up From $3.000M YoY
Prelude Therapeutics (NASDAQ:PRLD) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.36) by 28.77 percent. This is a 39.53 percent increase over losses of $(0.43) per share
11-12 20:06
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Prelude Therapeutics reported Q3 2025 financials with $58.2M in cash and a runway into 2027. Key pipeline updates include advancing JAK2V617F inhibitor and KAT6A degrader candidates, with IND filings expected in 2026. The company also presented preclinical data at ASH 2025 and expanded collaborations with Incyte and AbCellera. Research and development expenses decreased to $21.7M, and net loss was $19.7M. An investor conference call is scheduled ...
11-12 12:01
Prelude Therapeutics Signs Option Agreement with Incyte
Prelude Therapeutics ( ($PRLD) ) has provided an update. On November 3, 2025, P...
11-04 22:18
Market-Moving News for November 4th
PRLD: 70% | Prelude Therapeutics Signs Agreement For Incyte To Acquire JAK2V617F JH2 Inhibitor Program In Development For Patients With Myeloproliferative Neoplasms NSP: -32% | Insperity shares are trading
11-04 20:24
美股牛股 | AI军备竞赛持续加码！CIFR大涨超22%，与亚马逊达成数十亿美元交易；艾马克技术涨超17%
AI军备竞赛持续加码！CIFR大涨超22%，与亚马逊达成数十亿美元交易；艾马克技术涨超17%，黄仁勋证实：英伟达携手其生产Blackwell芯片>>
11-04 13:38
Prelude Therapeutics Announces Strategic Business Update
Prelude Therapeutics has entered into an exclusive option agreement with Incyte Corporation for its JAK2V617F mutant selective inhibitor program, involving a $35 million upfront payment, a $25 million equity investment, and potential additional funds if the option is exercised. The company is prioritizing development of its KAT6A selective degrader program for ER+ breast cancer, targeting clinical development in 2026, while pausing its SMARCA2 pr...
11-04 12:05
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
Prelude Therapeutics announced the presentation of two abstracts at the ASH 67th Annual Meeting highlighting its JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates (DACs). The JAK2 inhibitors, which bind to the JH2 "deep pocket" where the V617F mutation resides, showed mutant-specific inhibition in MPN models, with potential for disease modification. The CALR-targeted DACs deliver CDK9 degrader payloads, selectiv...
11-03 14:01
